Ret-mediated mitogenesis requires Src kinase activity.
暂无分享,去创建一个
M. Barone | M. Santoro | A. Fusco | R. Melillo | R. Visconti | P. P. Di Fiore | A. Cirafici | F. Carlomagno | G. Vecchio | B. Matoskova | G. Lupoli
[1] G. D. Vita,et al. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease. , 1998, Endocrinology.
[2] M. Santoro,et al. Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKs): evidence for a divergence of the ERKs and JNKs pathways induced by Ret , 1998, Oncogene.
[3] Susan S. Taylor,et al. Shc and Enigma Are Both Required for Mitogenic Signaling by Ret/ptc2 , 1998, Molecular and Cellular Biology.
[4] T. Boone,et al. GFRα-2 and GFRα-3 Are Two New Receptors for Ligands of the GDNF Family , 1997, The Journal of Biological Chemistry.
[5] T. Pawson,et al. Signaling through scaffold, anchoring, and adaptor proteins. , 1997, Science.
[6] Hua Yu,et al. Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential , 1997, Oncogene.
[7] Jimi Adu,et al. Neurturin responsiveness requires a GPI-linked receptor and the Ret receptor tyrosine kinase , 1997, Nature.
[8] Barbara Moffat,et al. A GPI-linked protein that interacts with Ret to form a candidate neurturin receptor , 1997, Nature.
[9] T. Pawson,et al. RET alternate splicing influences the interaction of activated RET with the SH2 and PTB domains of Shc, and the SH2 domain of Grb2 , 1997, Oncogene.
[10] M. Borrello,et al. Identification of Shc docking site on Ret tyrosine kinase , 1997, Oncogene.
[11] G. Botti,et al. Development of mammary and cutaneous gland tumors in transgenic mice carrying the RET/PTC1 oncogene. , 1996, Oncogene.
[12] N. Asai,et al. A Mutation at Tyrosine 1062 in MEN2A-Ret and MEN2B-Ret Impairs Their Transforming Activity and Association with Shc Adaptor Proteins* , 1996, The Journal of Biological Chemistry.
[13] G. D. Vita,et al. A potential pathogenetic mechanism for multiple endocrine neoplasia type 2 syndromes involves ret-induced impairment of terminal differentiation of neuroepithelial cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[14] T. Hunter,et al. Requirement for c-Src Catalytic Activity and the SH3 Domain in Platelet-derived Growth Factor BB and Epidermal Growth Factor Mitogenic Signaling* , 1996, The Journal of Biological Chemistry.
[15] S. Courtneidge,et al. The Src SH3 Domain Is Required for DNA Synthesis Induced by Platelet-derived Growth Factor and Epidermal Growth Factor* , 1996, The Journal of Biological Chemistry.
[16] J. Louis,et al. GDNF–Induced Activation of the Ret Protein Tyrosine Kinase Is Mediated by GDNFR-α, a Novel Receptor for GDNF , 1996, Cell.
[17] Vittorio,et al. Molecular heterogeneity of RET loss of function in Hirschsprung's disease. , 1996, The EMBO journal.
[18] Susan S. Taylor,et al. Mitogenic Signaling by Ret/ptc2 Requires Association with Enigma via a LIM Domain* , 1996, The Journal of Biological Chemistry.
[19] Pier Paolo Di Fiore,et al. Direct Association between the Ret Receptor Tyrosine Kinase and the Src Homology 2-containing Adapter Protein Grb7 (*) , 1996, The Journal of Biological Chemistry.
[20] M. Borrello,et al. The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma , 1996, Molecular and cellular biology.
[21] B. Pasini,et al. RET mutations in human disease. , 1996, Trends in genetics : TIG.
[22] R. A. Decker,et al. Oncogenic RET Receptors Display Different Autophosphorylation Sites and Substrate Binding Specificities (*) , 1996, The Journal of Biological Chemistry.
[23] J. Bos,et al. Ret receptor tyrosine kinase activates extracellular signal-regulated kinase 2 in SK-N-MC cells. , 1995, Oncogene.
[24] M. Barone,et al. Myc but not Fos rescue of PDGF signalling block caused by kinase-inactive Src , 1995, Nature.
[25] M. Santoro,et al. Molecular defects in thyroid carcinomas: role of the RET oncogene in thyroid neoplastic transformation. , 1995, European journal of endocrinology.
[26] M. Santoro,et al. Expression of the RET oncogene induces differentiation of SK-N-BE neuroblastoma cells. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[27] Susan S. Taylor,et al. Tyrosines outside the Kinase Core and Dimerization Are Required for the Mitogenic Activity of RET/ptc2 (*) , 1995, The Journal of Biological Chemistry.
[28] A. Pandey,et al. The Ret Receptor Protein Tyrosine Kinase Associates with the SH2-containing Adapter Protein Grb10 (*) , 1995, The Journal of Biological Chemistry.
[29] W. Muller,et al. Direct and specific interaction of c-Src with Neu is involved in signaling by the epidermal growth factor receptor. , 1995, Oncogene.
[30] G. D. Vita,et al. Activated RET/PTC oncogene elicits immediate early and delayed response genes in PC12 cells. , 1995, Oncogene.
[31] M. Borrello,et al. Loss of function effect of RET mutations causing Hirschsprung disease , 1995, Nature Genetics.
[32] M. Roussel,et al. DNA synthesis induced by some but not all growth factors requires Src family protein tyrosine kinases , 1995, Molecular and cellular biology.
[33] al. et,et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B , 1995, Science.
[34] A Greco,et al. The oncogenic versions of the Ret and Trk tyrosine kinases bind Shc and Grb2 adaptor proteins. , 1994, Oncogene.
[35] L. Philipson,et al. CHOP (GADD153) and its oncogenic variant, TLS-CHOP, have opposing effects on the induction of G1/S arrest. , 1994, Genes & development.
[36] B. Ponder,et al. Mutations of the RET proto-oncogene in Hirschsprung's disease , 1994, Nature.
[37] B. Pasini,et al. Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease , 1994, Nature.
[38] M. Luther,et al. Involvement of pp60c-src with two major signaling pathways in human breast cancer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[39] M. Santoro,et al. An epidermal growth factor receptor/ret chimera generates mitogenic and transforming signals: evidence for a ret-specific signaling pathway , 1994, Molecular and cellular biology.
[40] W. Muller,et al. Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity , 1994, Molecular and cellular biology.
[41] Jonathan A. Cooper,et al. The when and how of Src regulation , 1993, Cell.
[42] T. Pawson,et al. SH2 domains recognize specific phosphopeptide sequences , 1993, Cell.
[43] M. Roussel,et al. Activation of Src family kinases by colony stimulating factor‐1, and their association with its receptor. , 1993, The EMBO journal.
[44] M. Santoro,et al. The TRK and RET tyrosine kinase oncogenes cooperate with ras in the neoplastic transformation of a rat thyroid epithelial cell line. , 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[45] G. Staal,et al. Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. , 1992, Cancer research.
[46] J. Hoxie,et al. Activation of Fc gamma RII induces tyrosine phosphorylation of multiple proteins including Fc gamma RII. , 1992, The Journal of biological chemistry.
[47] S. Courtneidge,et al. Association of Fyn with the activated platelet-derived growth factor receptor: requirements for binding and phosphorylation. , 1992, Oncogene.
[48] J. Brugge,et al. Signal transduction by nerve growth factor and fibroblast growth factor in PC12 cells requires a sequence of src and ras actions , 1991, The Journal of cell biology.
[49] S. Courtneidge,et al. Association between the PDGF receptor and members of the src family of tyrosine kinases , 1990, Cell.
[50] S. Aaronson,et al. EGF receptor and erbB-2 tyrosine kinase domains confer cell specificity for mitogenic signaling. , 1990, Science.
[51] M. Santoro,et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas , 1990, Cell.
[52] J. Pipas,et al. pp60c-src activation in human colon carcinoma. , 1989, The Journal of clinical investigation.
[53] T. Iwamoto,et al. Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. , 1988, Oncogene.
[54] B. Groner,et al. Prolactin regulation of beta‐casein gene expression and of a cytosolic 120‐kd protein in a cloned mouse mammary epithelial cell line. , 1988, The EMBO journal.
[55] A. Fusco,et al. One- and two-step transformations of rat thyroid epithelial cells by retroviral oncogenes , 1987, Molecular and cellular biology.
[56] C R King,et al. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.
[57] P. Cohen,et al. Analysis of pp60c-src protein kinase activity in human tumor cell lines and tissues. , 1986, The Journal of biological chemistry.
[58] H. Rübsamen,et al. Expression of pp60c-src protein kinase in adult and fetal human tissue: high activities in some sarcomas and mammary carcinomas. , 1983, Cancer research.